Traders Are Getting Smarter About the Vaccine Race

Investors watching the COVID-19 vaccine development process could be forgiven for thinking it’s not so hard. The effort has moved extraordinarily quickly so far, and with few hiccups. That isn’t how things usually go, especially for new diseases. The world got a reminder Tuesday as AstraZeneca Plc paused the trial of its leading candidate, developed with Oxford University, to investigate a single volunteer’s illness. It’s easy to panic; a setback like this could mean big trouble for AstraZeneca’s efforts, and it raises worries about whether any vaccine will ultimately succeed, or if one does, how long the process … (full story)

Let's Have A Chat ​


please, upload jpg, jpeg, png or pdf files only